We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Dasatinib (Sprycel) — senolytic use
A leukemia chemotherapy drug (tyrosine-kinase inhibitor) used off-label — combined with quercetin (the 'D+Q' protocol) — as a senolytic to clear senescent 'zombie' cells. Animal data are striking and the first small human pilots are promising, but it is a serious cancer drug with significant toxicity and almost no human longevity evidence. Prescription drug, not a supplement.
Prescription medication — not a dietary supplement
Dasatinib is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Dasatinib studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2015–2026 with a typical study size of 37 participants.
Based on 33 studies · 2 meta-analyses · 18 RCTs · 853 total participants
Confidence
High confidenceBy outcome
Dasatinib (with quercetin) is the founding senolytic with strong animal lifespan/function data and encouraging first-in-human pilots, but human evidence is tiny and mostly open-label with no longevity outcomes, and it is a serious leukemia drug with significant toxicity — so the longevity use is early and high-risk.
24 rigorous studies
22 randomized trials · 2 meta-analyses · 1 systematic reviews
Our evidence rating for Dasatinib is accountable to this entire body of rigorous research indexed in PubMed — not a hand-picked subset.
PubMed · as of Jul 2026
74 trials ongoing or recruiting · 202 completed on ClinicalTrials.gov
99 of the completed trials have posted results
Registered trials show research momentum for Dasatinib, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Aug 2026
Dasatinib is a potent tyrosine-kinase inhibitor FDA-approved to treat chronic myeloid leukemia and Philadelphia-chromosome-positive ALL. In geroscience it is used off-label as a senolytic — a drug that selectively kills senescent ('zombie') cells, which accumulate with age and drive chronic inflammation.
It is almost always paired with the flavonoid quercetin (the 'D+Q' protocol), because dasatinib and quercetin clear different senescent-cell types; quercetin is already a common dietary supplement.
The preclinical case is strong: D+Q improved physical function and extended lifespan in old mice and cleared senescent cells in multiple tissues, and it gave the field its founding senolytic.
Early human translation is genuinely promising but very preliminary: a first-in-human open-label pilot in idiopathic pulmonary fibrosis reported improved physical function, and a small clinical-trial report showed D+Q reduced senescent-cell markers in tissue from people with diabetic kidney disease.
The honest reality is that these are tiny, short, mostly open-label studies with no longevity outcomes, and dasatinib itself is a serious oncology drug: it carries risks of myelosuppression, bleeding, fluid retention/pleural effusions, QT prolongation, and cardiac effects, and has major drug interactions.
Senolytic protocols use intermittent 'hit-and-run' dosing (a few days, periodically) to limit exposure, but the right human dose/schedule for longevity is unknown. This is a prescription chemotherapy agent used off-label, not a supplement, and self-experimentation is risky.
The score reflects compelling preclinical senolytic data and encouraging early pilots against minimal human evidence and a serious toxicity profile.
Dasatinib disables the pro-survival ('SCAP') pathways senescent cells depend on, triggering their apoptosis. Paired with quercetin to cover complementary senescent-cell types.
Its broad TKI activity (BCR-ABL, SRC family, ephrin receptors) underlies both the senolytic effect and the systemic toxicity.
Clearing senescent cells lowers the senescence-associated secretory phenotype — the chronic inflammatory signaling implicated in aging.
How Dasatinib works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Contraindicated — cytotoxic, teratogenic potential.
Avoid or use with great caution — additive bleeding risk.
Avoid — risk of effusions and arrhythmia.
Strong inhibitors (ketoconazole, grapefruit) raise dasatinib toxicity; inducers (rifampin) reduce efficacy.
Markedly reduce dasatinib absorption.
Dasatinib inhibits platelet function — additive bleeding risk.
Tip: A hallmark oncology toxicity; relevant mainly to continuous dosing, less to brief senolytic courses — but monitor.
Tip: Characteristic dasatinib effect; seek care for shortness of breath.
Tip: Platelet inhibition; caution with anticoagulants.
Tip: Avoid with other QT-prolonging drugs or cardiac disease.
Dasatinib has an evidence score of 3.5/10 — emerging evidence based on 10 indexed studies. A leukemia chemotherapy drug (tyrosine-kinase inhibitor) used off-label — combined with quercetin (the 'D+Q' protocol) — as a senolytic to clear senescent 'zombie' cells. Animal data are striking and the first small human pilots are promising, but it is a serious cancer drug with significant toxicity and almost no human longevity evidence. Prescription drug, not a supplement. Representative study: PMID 29988130.
The commonly studied dose of Dasatinib is No validated longevity dose. Senolytic research uses intermittent 'hit-and-run' D+Q (e.g. dasatinib 100 mg + quercetin for ~2–3 days, repeated periodically) — investigational and only appropriate under medical supervision. Approved leukemia dosing is continuous and higher.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Timing is flexible for Dasatinib — consistent daily use matters more than the time of day. Avoid acid reducers (they cut absorption) and grapefruit/CYP3A4 inhibitors (which raise levels).
Dasatinib should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are myelosuppression (low blood counts), fluid retention / pleural effusion, bleeding / bruising. Use caution if any of these apply to you: Pregnancy / breastfeeding; Active bleeding or significant thrombocytopenia; Significant cardiac disease / QT prolongation.
CoQ10
Likely helpsA lipid-soluble antioxidant central to mitochondrial energy production, with the strongest trial support for fertility/IVF outcomes and heart failure.
Berberine
Likely helpsActivates AMPK to regulate blood sugar, improve insulin sensitivity, and support lipid metabolism — comparable to metformin in some trials.
Beta-Sitosterol
Likely helpsPlant sterol that reduces BPH urinary symptoms in clinical trials and blocks intestinal cholesterol absorption.
Alpha Lipoic Acid
Likely helpsUniversal antioxidant that works in both water and fat, supporting blood sugar control, nerve health, and cellular energy.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 33 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research